EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Nova Mentis Life Science Corp (NMLSF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Nova Mentis Life Science Corp $0.03, price $0.07, upside -54.5%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

NM Nova Mentis Life Science Corp logo Thin data Oct 2, 2026

Nova Mentis Life Science Corp

NMLSF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0299 · Strongly overvalued (−54.5%)
!Quality 37/100
!Mixed Growth (revenue 3y +30.3 %/yr)
!negative free cash flow
!Trails peers (1/7)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Nova Mentis Life Science Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.23 $0.0101 Fair Value $0.0299 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range $0.0101 – $1.23 · fair‑value band $0.0299 – $0.0360 · the $0.0657 price screens above the $0.0299 fair value. Dashed = 300-day average. As of Oct 2, 2026.

Follow Nova Mentis Life Science in your weekly email

Every Wednesday you see whether Nova Mentis Life Science is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products.

Show more

Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies, including the development across various product lines, including BrainQ, BrainBalls, and Holy Crap. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.

Stock analysis

Nova Mentis Life Science Corp (NMLSF) currently trades at $0.0657, while our model-based Fair Value estimate is $0.0299, 54.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0299 (bear) to $0.0360 (bull), the price of $0.0657 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Nova Mentis Life Science Corp reported revenue of C$0 in FY2025 versus C$1.5K in FY2021. Reported net income was −C$1.4M in FY2025.

Key figures

Market cap $3.1M · P/S ratio 33.0 · EPS (TTM) $−0.0100 · Return on equity −99.3% · Return on assets (EBIT) −1,043% · Operating margin −231% · Revenue (TTM) $135K · Revenue growth (YoY) −78.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 550% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −54%, NMLSF screens richer than that median.

Fair Value models

Bear $0.0299 Fair Value $0.0299 Bull $0.0360
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0100 $0.0100 $0.0100 53
All 1 models by family
Asset-Based
NCAV (Graham) $0.0100 $0.0100 $0.0100 53

Open the full fair value analysis →

Notify me when NMLSF reaches fair value

Put NMLSF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 43 · Market factors (momentum, volatility) 44

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 59
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.3%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15,564.9% (2019) → −4,732.5% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NMLSF screens overvalued: fair value 54% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Nova Mentis Life Science Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Above median
Fair Value upside −51.2% · Below median
Profitability
Return on assets −43.7% · Bottom 25%
Growth and dividend
Revenue growth −78.8% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.40× · Pricier than median
P/S (TTM) 22.97× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nova Mentis Life Science Corp · Fair Value
$0.0299 −54%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Nova Mentis Life Science Corp Fair Value". https://www.fairvalue-calculator.com/stock/NMLSF

Frequently asked questions

Is Nova Mentis Life Science Corp (NMLSF) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $0.0299 versus a price of $0.0657, about −54% upside (overvalued).
What is the fair value of NMLSF?
Our model-based fair value for Nova Mentis Life Science Corp is $0.0299 (as of Oct 2, 2026), built from audited fundamentals. The current price: $0.0657.
What is the quality score of NMLSF?
Nova Mentis Life Science Corp has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nova Mentis Life Science Corp (NMLSF)?
Our model-based price target is the fair value of $0.0299 (as of Oct 2, 2026) from 1 valuation models. Cautious scenario $0.0299, optimistic scenario $0.0360. It is a calculation from audited fundamentals, not an analyst target.
What is the Nova Mentis Life Science Corp stock forecast for 2026?
Our models put fair value at $0.0299, about −54% upside versus a price of $0.0657 (overvalued). Cautious scenario $0.0299, optimistic scenario $0.0360. The calculation is refreshed regularly with new filings.
What is the revenue of Nova Mentis Life Science Corp (NMLSF)?
Nova Mentis Life Science Corp reported trailing-twelve-month revenue of about $135K (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Nova Mentis Life Science Corp (NMLSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nova Mentis Life Science Corp it is $0.0299 per share (as of Oct 2, 2026), against a price of $0.0657. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Nova Mentis Life Science Corp stock overvalued or undervalued in 2026?
As of Oct 2, 2026, NMLSF trades above its calculated fair value: price $0.0657, fair value $0.0299, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NMLSF?
No. The price is what the market pays today ($0.0657); the fair value is what the company's own numbers justify ($0.0299). For Nova Mentis Life Science Corp the two are $0.0358 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nova Mentis Life Science Corp worth?
The market values Nova Mentis Life Science Corp at about $3.1M (market capitalisation, as of Oct 2, 2026). Per share that is $0.0657; our models calculate a fair value of $0.0299 per share.
What do the bullish and bearish scenarios say about NMLSF?
Our models span a range for Nova Mentis Life Science Corp: cautious scenario $0.0299, base $0.0299, optimistic $0.0360 per share (as of Oct 2, 2026, price $0.0657). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nova Mentis Life Science Corp (NMLSF)?
Balance-sheet figures for Nova Mentis Life Science Corp (as of Oct 2, 2026): return on equity −99.3%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is NMLSF from its 52-week high?
Nova Mentis Life Science Corp trades at $0.0657, about 47% below its 52-week high of $0.1242 and 550% above the low of $0.0101 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0299 is for.
Which stocks are comparable to Nova Mentis Life Science Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nova Mentis Life Science Corp stock attractive at the current price?
The data as of Oct 2, 2026: price $0.0657, calculated fair value $0.0299 (−54%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NMLSF calculated?
We run Nova Mentis Life Science Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0299, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Nova Mentis Life Science Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nova Mentis Life Science Corp (NMLSF)?
The closing price on Oct 2, 2026 was $0.0657. Our model-based fair value is $0.0299, about −54% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nova Mentis Life Science Corp right now?
The price sits above even our optimistic bull case ($0.0360). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Nova Mentis Life Science Corp

How large is the market capitalisation of Nova Mentis Life Science Corp (NMLSF)?
The market capitalisation of Nova Mentis Life Science Corp is $3.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nova Mentis Life Science Corp (NMLSF)?
The price-to-sales ratio of Nova Mentis Life Science Corp is 33.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nova Mentis Life Science Corp (NMLSF)?
Earnings per share at Nova Mentis Life Science Corp are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nova Mentis Life Science Corp (NMLSF)?
The return on equity (ROE) of Nova Mentis Life Science Corp is −99.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nova Mentis Life Science Corp (NMLSF)?
On an EBIT basis the return on assets of Nova Mentis Life Science Corp is −1,043% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nova Mentis Life Science Corp (NMLSF)?
The operating margin of Nova Mentis Life Science Corp is −231% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nova Mentis Life Science Corp (NMLSF)?
Revenue at Nova Mentis Life Science Corp is growing −78.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nova Mentis Life Science Corp (NMLSF) generate?
The free cash flow of Nova Mentis Life Science Corp is −$717K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nova Mentis Life Science Corp (NMLSF) hold?
Nova Mentis Life Science Corp holds more cash than debt, $1.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Nova Mentis Life Science Corp in the live analysis

One click puts Nova Mentis Life Science Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.